Show simple item record

dc.contributor.authorHyder, Z
dc.contributor.authorHarkness, EF
dc.contributor.authorWoodward, ER
dc.contributor.authorBowers, NL
dc.contributor.authorPereira, M
dc.contributor.authorWallace, AJ
dc.contributor.authorHowell, Sacha J
dc.contributor.authorHowell, Anthony
dc.contributor.authorLalloo, F
dc.contributor.authorNewman, WG
dc.contributor.authorSmith, MJ
dc.contributor.authorEvans, D Gareth R
dc.date.accessioned2020-03-27T09:28:04Z
dc.date.available2020-03-27T09:28:04Z
dc.date.issued2020en
dc.identifier.citationHyder Z, Harkness EF, Woodward ER, Bowers NL, Pereira M, Wallace AJ, et al. Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer. Cancers (Basel). 2020;12.en
dc.identifier.pmid32045981en
dc.identifier.doi10.3390/cancers12020378 [doi]en
dc.identifier.urihttp://hdl.handle.net/10541/622849
dc.description.abstractEarly age at diagnosis of breast cancer is a known risk factor for hereditary predisposition and some studies show a high risk of contralateral breast cancer in BRCA1 carriers diagnosed at very young ages. However, little is published on the risk of TP53 carriers. 397 women with breast cancer diagnosed <36 years of age were obtained from three sources: (i) a population-based study of 283 women diagnosed sequentially from 1980-1997 in North-West England, (ii) referrals to the Genomic Medicine Department at St Mary's Hospital from 1990-2018, and (iii) individuals from (i) and the Family History Clinic at Wythenshawe Hospital South Manchester who tested negative for pathogenic variants (PV) in all three genes. Sequencing of BRCA1, BRCA2, and TP53 genes was carried out alongside tests for copy number for PV on all referred women. Rates of contralateral breast cancer were censored at death, last assessment, or risk-reducing mastectomy. In total, 47 TP53, 218 BRCA1, and 132 BRCA2 PV carriers were identified with breast cancer diagnosed aged 35 years and under, as well as a representative sample of 261 not known to carry a PV in BRCA1, BRCA2, and TP53. Annual rates of contralateral breast cancer (and percentage of synchronous breast cancers) were TP53: 7.03% (4.3%), BRCA1: 3.57% (1.8%), and BRCA2: 2.63% (1.5%). In non-PV carriers, contralateral rates in isolated presumed/tested non-carrier cases with no family history were 0.56%, and for those with a family history, 0.69%. Contralateral breast cancer rates are substantial in TP53, BRCA1, and BRCA2 PV carriers diagnosed with breast cancer aged 35 and under. Women need to be advised to help make informed decisions on contralateral mastectomy, guided by life expectancy from their index tumor.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.3390/cancers12020378 [doi]en
dc.titleRisk of contralateral breast cancer in women with and without pathogenic variants in BRCA1, BRCA2, and TP53 genes in women with very early-onset (<36 Years) breast canceren
dc.typeArticleen
dc.contributor.departmentManchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester M13 9WLen
dc.identifier.journalCancersen
dc.description.noteen]
refterms.dateFOA2020-03-31T08:48:32Z


Files in this item

Thumbnail
Name:
32045981.pdf
Size:
1021.Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record